Rituximab is frequently used to treat a variety of B-cell lymphoma. Rituximab alone can produce significant response rates and long-term remissions in several B cell malignancies, whereas combining rituximab with chemotherapy improves overall survival in others. Rituximab is an important part of the treatment for anti-B cell malignancies, although it does not work for everyone, and resistance to it is prevalent. In order to further develop rituximab, which is already a highly effective treatment, it is critical to understand the pathways by which it elicits anti-tumor responses. Diffuse large B-cell lymphoma (DLBCL) is a kind of lymphoma that affects B cells, which are responsible for antibody production.
No takes yet. Share an insight, caveat, or question.
Jena et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: